Symbols / ACIU $3.06 +6.62% AC Immune SA

Healthcare • Biotechnology • Switzerland • NGM
ACIU Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Fundamentals
Scroll to Statements
Market Cap 311.43M Enterprise Value 216.68M Income -70.45M Sales 3.57M Book/sh 0.56 Cash/sh 0.92
Dividend Yield — Payout 0.00% Employees 90 IPO — P/E — Forward P/E 4.92
PEG — P/S 87.16 P/B 5.44 P/C — EV/EBITDA -3.21 EV/Sales 60.65
Quick Ratio 0.97 Current Ratio 1.02 Debt/Eq 10.12 LT Debt/Eq — EPS (ttm) -0.90 EPS next Y 0.62
EPS Growth — Revenue Growth -70.30% Earnings 2026-04-29 ROA -22.35% ROE -89.65% ROIC —
Gross Margin 0.00% Oper. Margin -42.62% Profit Margin 0.00% Shs Outstand 101.77M Shs Float 38.80M Short Float 6.07%
Short Ratio 11.21 Short Interest — 52W High 4.00 52W Low 1.51 Beta 1.63 Avg Volume 281.46K
Volume 149.32K Target Price $9.10 Recom None Prev Close $2.87 Price $3.06 Change 6.62%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$9.10
Mean price target
2. Current target
$3.06
Latest analyst target
3. DCF / Fair value
$-7.39
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.06
Low
$7.00
High
$12.08
Mean
$9.10

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-16 reit BTIG Buy → Buy $8
2025-11-04 reit BTIG Buy → Buy $8
2025-09-08 reit BTIG Buy → Buy $8
2025-05-01 main HC Wainwright & Co. Buy → Buy $12
2025-04-03 reit HC Wainwright & Co. Buy → Buy $16
2025-03-14 reit HC Wainwright & Co. Buy → Buy $16
2024-11-15 reit HC Wainwright & Co. Buy → Buy $16
2024-11-06 reit HC Wainwright & Co. Buy → Buy $16
2024-09-18 reit HC Wainwright & Co. Buy → Buy $16
2024-05-31 init BTIG — → Buy $8
2024-03-15 reit HC Wainwright & Co. Buy → Buy $16
2023-11-13 reit HC Wainwright & Co. Buy → Buy $16
2023-08-07 reit HC Wainwright & Co. Buy → Buy $16
2023-06-28 reit HC Wainwright & Co. Buy → Buy $16
2023-05-01 reit HC Wainwright & Co. — → Buy $16
2023-04-19 reit HC Wainwright & Co. — → Buy $16
2023-03-17 reit HC Wainwright & Co. — → Buy $16
2022-07-11 main SVB Leerink — → Outperform $10
2021-12-20 main SVB Leerink — → Outperform $15
2021-03-24 main HC Wainwright & Co. — → Buy $16
News
RSS: Latest ACIU news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-15 PFEIFER ANDREA M. A PH.D. Chief Executive Officer — 10,000 $3.14 $31,425
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
3.57
-86.92%
27.31
+84.51%
14.80
+276.14%
3.94
Operating Revenue
3.57
-86.92%
27.31
+84.51%
14.80
+276.14%
3.94
Operating Expense
72.44
-9.10%
79.69
+16.46%
68.42
-8.50%
74.78
Research And Development
56.44
-9.80%
62.57
+14.58%
54.61
-9.50%
60.34
Selling General And Administration
11.65
+1.91%
11.43
+8.11%
10.58
+10.37%
9.58
General And Administrative Expense
11.65
+1.91%
11.43
+8.11%
10.58
+10.37%
9.58
Salaries And Wages
11.65
+1.91%
11.43
+8.11%
10.58
+10.37%
9.58
Other Operating Expenses
2.73
-39.71%
4.53
+108.56%
2.17
-55.35%
4.86
Total Expenses
72.44
-9.10%
79.69
+16.46%
68.42
-8.50%
74.78
Operating Income
-68.86
-31.47%
-52.38
+2.32%
-53.62
+24.31%
-70.85
Total Operating Income As Reported
-69.32
-32.34%
-52.38
+2.32%
-53.62
+24.31%
-70.85
EBITDA
-67.75
-39.36%
-48.62
+6.20%
-51.83
+23.81%
-68.03
Normalized EBITDA
-64.50
-37.17%
-47.02
+6.64%
-50.37
+26.39%
-68.42
Reconciled Depreciation
2.50
+15.77%
2.16
-2.39%
2.21
-6.10%
2.36
EBIT
-70.26
-38.35%
-50.78
+6.04%
-54.05
+23.21%
-70.39
Total Unusual Items
-3.26
-103.88%
-1.60
-8.93%
-1.47
-473.28%
0.39
Total Unusual Items Excluding Goodwill
-3.26
-103.88%
-1.60
-8.93%
-1.47
-473.28%
0.39
Special Income Charges
-0.46
0.00
0.00
—
Restructuring And Mergern Acquisition
0.46
0.00
0.00
—
Net Income
-70.45
-38.36%
-50.92
+6.12%
-54.23
+23.35%
-70.75
Pretax Income
-70.45
-38.37%
-50.91
+6.10%
-54.22
+23.35%
-70.74
Net Non Operating Interest Income Expense
1.67
-45.35%
3.06
+252.88%
0.87
+403.50%
-0.29
Interest Expense Non Operating
0.19
+43.61%
0.13
-24.43%
0.18
-50.42%
0.35
Net Interest Income
1.67
-45.35%
3.06
+252.88%
0.87
+403.50%
-0.29
Interest Expense
0.19
+43.61%
0.13
-24.43%
0.18
-50.42%
0.35
Interest Income Non Operating
1.86
-41.65%
3.20
+206.13%
1.04
+1413.04%
0.07
Interest Income
1.86
-41.65%
3.20
+206.13%
1.04
+1413.04%
0.07
Other Income Expense
-3.26
-103.88%
-1.60
-8.93%
-1.47
-473.28%
0.39
Gain On Sale Of Security
-2.80
-75.41%
-1.60
-8.93%
-1.47
-473.28%
0.39
Tax Provision
0.00
-100.00%
0.00
-70.00%
0.01
-23.08%
0.01
Tax Rate For Calcs
0.00
-100.00%
0.00
+0.00%
0.00
-34.62%
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-0.14
-8.93%
-0.12
-344.07%
0.05
Net Income Including Noncontrolling Interests
-70.45
-38.36%
-50.92
+6.12%
-54.23
+23.35%
-70.75
Net Income From Continuing Operation Net Minority Interest
-70.45
-38.36%
-50.92
+6.12%
-54.23
+23.35%
-70.75
Net Income From Continuing And Discontinued Operation
-70.45
-38.36%
-50.92
+6.12%
-54.23
+23.35%
-70.75
Net Income Continuous Operations
-70.45
-38.36%
-50.92
+6.12%
-54.23
+23.35%
-70.75
Normalized Income
-67.19
-35.86%
-49.45
+6.50%
-52.89
+25.61%
-71.09
Net Income Common Stockholders
-70.45
-38.36%
-50.92
+6.12%
-54.23
+23.35%
-70.75
Diluted EPS
-0.70
-37.25%
-0.51
+20.31%
-0.64
+24.71%
-0.85
Basic EPS
-0.70
-37.25%
-0.51
+20.31%
-0.64
+24.71%
-0.85
Basic Average Shares
100.75
+0.92%
99.84
+17.88%
84.69
+1.36%
83.55
Diluted Average Shares
100.75
+0.92%
99.84
+17.88%
84.69
+1.36%
83.55
Diluted NI Availto Com Stockholders
-70.45
-38.36%
-50.92
+6.12%
-54.23
+23.35%
-70.75
Depreciation Amortization Depletion Income Statement
1.62
+40.24%
1.15
+7.66%
1.07
—
Depreciation And Amortization In Income Statement
1.62
+40.24%
1.15
+7.66%
1.07
—
Depreciation Income Statement
1.62
+40.24%
1.15
+7.66%
1.07
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
154.25
-33.20%
230.91
+26.31%
182.81
-1.68%
185.94
Current Assets
96.72
-43.76%
171.99
+37.43%
125.15
-2.30%
128.09
Cash Cash Equivalents And Short Term Investments
91.41
-44.76%
165.49
+60.59%
103.05
-15.94%
122.59
Cash And Cash Equivalents
26.80
-26.13%
36.27
-53.79%
78.49
+148.51%
31.59
Other Short Term Investments
64.62
-49.99%
129.21
+426.24%
24.55
-73.02%
91.00
Receivables
1.34
-39.26%
2.20
-85.94%
15.67
+1858.50%
0.80
Accounts Receivable
—
0.00
-100.00%
14.80
0.00
Other Receivables
0.44
-64.60%
1.24
+327.15%
0.29
-45.30%
0.53
Taxes Receivable
0.90
-6.46%
0.96
+66.38%
0.58
+115.30%
0.27
Prepaid Assets
3.97
-7.67%
4.30
-33.17%
6.44
+36.72%
4.71
Total Non Current Assets
57.53
-2.36%
58.92
+2.18%
57.66
-0.32%
57.84
Net PPE
6.53
-19.29%
8.09
+17.49%
6.88
-2.59%
7.07
Gross PPE
20.24
-1.52%
20.56
+14.97%
17.88
+8.96%
16.41
Accumulated Depreciation
-13.72
-10.01%
-12.47
-13.39%
-11.00
-17.69%
-9.34
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
4.47
-16.00%
5.32
+54.38%
3.45
+27.25%
2.71
Machinery Furniture Equipment
2.95
+3.98%
2.84
+11.74%
2.54
+10.68%
2.29
Construction In Progress
—
0.00
0.00
-100.00%
0.00
Other Properties
10.94
+3.79%
10.54
+2.96%
10.23
+4.79%
9.77
Leases
1.89
+1.45%
1.86
+12.09%
1.66
+1.34%
1.64
Goodwill And Other Intangible Assets
50.42
+0.00%
50.42
+0.00%
50.42
+0.00%
50.42
Other Intangible Assets
50.42
+0.00%
50.42
+0.00%
50.42
+0.00%
50.42
Investments And Advances
0.58
+40.72%
0.41
+14.96%
0.36
+0.00%
0.36
Other Non Current Assets
0.00
—
—
—
Total Liabilities Net Minority Interest
109.37
-7.82%
118.64
+435.13%
22.17
+30.83%
16.95
Current Liabilities
94.69
-6.09%
100.84
+642.77%
13.58
+18.25%
11.48
Payables And Accrued Expenses
10.13
-31.32%
14.76
+15.59%
12.77
+23.39%
10.35
Payables
2.07
-22.20%
2.66
+58.31%
1.68
+80.73%
0.93
Accounts Payable
2.07
-22.20%
2.66
+58.31%
1.68
+80.73%
0.93
Current Accrued Expenses
8.07
-33.32%
12.10
+9.12%
11.09
+17.73%
9.42
Employee Benefits
8.65
-2.24%
8.84
+53.28%
5.77
+79.58%
3.21
Current Debt And Capital Lease Obligation
0.85
-16.96%
1.03
+52.68%
0.67
+22.63%
0.55
Current Capital Lease Obligation
0.85
-16.96%
1.03
+52.68%
0.67
+22.63%
0.55
Current Deferred Liabilities
83.71
-1.59%
85.06
+61534.78%
0.14
-76.49%
0.59
Current Deferred Revenue
83.71
-1.59%
85.06
+61534.78%
0.14
-76.49%
0.59
Total Non Current Liabilities Net Minority Interest
14.67
-17.58%
17.80
+107.16%
8.60
+57.24%
5.47
Long Term Debt And Capital Lease Obligation
3.69
-16.18%
4.40
+55.79%
2.83
+25.39%
2.25
Long Term Capital Lease Obligation
3.69
-16.18%
4.40
+55.79%
2.83
+25.39%
2.25
Non Current Deferred Liabilities
2.34
-48.71%
4.56
0.00
—
Non Current Deferred Revenue
2.34
-48.71%
4.56
0.00
—
Stockholders Equity
44.88
-60.02%
112.27
-30.11%
160.64
-4.94%
168.99
Common Stock Equity
44.88
-60.02%
112.27
-30.11%
160.64
-4.94%
168.99
Capital Stock
2.25
+1.21%
2.23
+6.56%
2.09
+16.25%
1.80
Common Stock
2.25
+1.21%
2.23
+6.56%
2.09
+16.25%
1.80
Share Issued
112.64
+1.20%
111.31
+6.58%
104.44
+16.26%
89.83
Ordinary Shares Number
101.74
+1.33%
100.41
+1.22%
99.20
+18.63%
83.62
Treasury Shares Number
10.90
+0.00%
10.90
+107.85%
5.24
-15.61%
6.21
Additional Paid In Capital
481.86
+0.70%
478.51
+0.76%
474.91
+10.10%
431.32
Retained Earnings
-439.02
-19.22%
-368.24
-16.46%
-316.20
-19.76%
-264.01
Gains Losses Not Affecting Retained Earnings
0.01
+240.00%
-0.01
+90.20%
-0.05
-610.00%
0.01
Treasury Stock
0.22
+0.00%
0.22
+107.62%
0.10
-15.32%
0.12
Total Equity Gross Minority Interest
44.88
-60.02%
112.27
-30.11%
160.64
-4.94%
168.99
Total Capitalization
44.88
-60.02%
112.27
-30.11%
160.64
-4.94%
168.99
Working Capital
2.03
-97.15%
71.16
-36.23%
111.58
-4.32%
116.61
Invested Capital
44.88
-60.02%
112.27
-30.11%
160.64
-4.94%
168.99
Total Debt
4.54
-16.33%
5.43
+55.19%
3.50
+24.85%
2.80
Capital Lease Obligations
4.54
-16.33%
5.43
+55.19%
3.50
+24.85%
2.80
Net Tangible Assets
-5.53
-108.94%
61.85
-43.88%
110.23
-7.04%
118.58
Tangible Book Value
-5.53
-108.94%
61.85
-43.88%
110.23
-7.04%
118.58
Foreign Currency Translation Adjustments
0.01
+240.00%
-0.01
+90.20%
-0.05
-610.00%
0.01
Investmentin Financial Assets
0.58
+40.72%
0.41
+14.96%
0.36
+0.00%
0.36
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-69.26
-205.19%
65.84
+209.00%
-60.41
+17.89%
-73.57
Cash Flow From Continuing Operating Activities
-69.26
-205.19%
65.84
+209.00%
-60.41
+17.89%
-73.57
Net Income From Continuing Operations
-70.45
-38.36%
-50.92
+6.12%
-54.23
+23.35%
-70.75
Depreciation Amortization Depletion
2.50
+15.77%
2.16
-2.39%
2.21
-6.10%
2.36
Depreciation
2.50
+15.77%
2.16
-2.39%
2.21
-6.10%
2.36
Depreciation And Amortization
2.50
+15.77%
2.16
-2.39%
2.21
-6.10%
2.36
Other Non Cash Items
0.92
+388.83%
0.19
-82.88%
1.10
+638.24%
-0.20
Pension And Employee Benefit Expense
-1.55
-15410.00%
-0.01
-101.13%
0.89
+64.14%
0.54
Stock Based Compensation
4.40
-19.63%
5.47
+25.32%
4.37
+31.08%
3.33
Operating Gains Losses
-1.57
-15560.00%
-0.01
-101.13%
0.89
+64.14%
0.54
Gain Loss On Sale Of PPE
-0.01
0.00
0.00
0.00
Change In Working Capital
-6.78
-106.30%
107.51
+809.20%
-15.16
-79.79%
-8.43
Change In Receivables
0.92
-93.22%
13.55
+191.13%
-14.87
-2566.00%
0.60
Changes In Account Receivables
0.00
-100.00%
14.80
+200.00%
-14.80
0.00
Change In Prepaid Assets
0.33
-84.54%
2.13
+222.14%
-1.75
-1.75%
-1.72
Change In Payables And Accrued Expense
-4.45
-289.49%
2.35
+23.23%
1.91
+126.53%
-7.19
Change In Accrued Expense
-3.86
-381.21%
1.37
+20.76%
1.14
+118.60%
-6.11
Change In Payable
-0.59
-160.59%
0.98
+26.88%
0.77
+171.76%
-1.07
Change In Other Working Capital
-3.57
-103.99%
89.48
+20028.29%
-0.45
-245.38%
-0.13
Investing Cash Flow
63.54
+160.35%
-105.29
-260.39%
65.64
+176.25%
23.76
Cash Flow From Continuing Investing Activities
63.54
+160.35%
-105.29
-260.39%
65.64
+176.25%
23.76
Net PPE Purchase And Sale
-0.89
-53.65%
-0.58
+28.09%
-0.80
+35.35%
-1.24
Purchase Of PPE
-0.90
-56.25%
-0.58
+28.09%
-0.80
+35.35%
-1.24
Sale Of PPE
0.01
0.00
0.00
0.00
Capital Expenditure
-0.90
-56.25%
-0.58
+28.09%
-0.80
+35.35%
-1.24
Net Investment Purchase And Sale
64.60
+161.72%
-104.66
-257.51%
66.45
+165.78%
25.00
Net Other Investing Changes
-0.17
-214.81%
-0.05
—
0.00
Financing Cash Flow
-1.02
+8.93%
-1.12
-102.59%
43.25
+3313.22%
-1.35
Cash Flow From Continuing Financing Activities
-1.02
+8.93%
-1.12
-102.59%
43.25
+3313.22%
-1.35
Net Issuance Payments Of Debt
-1.03
-50.22%
-0.68
-24.64%
-0.55
+3.69%
-0.57
Issuance Of Debt
—
—
0.00
0.00
Repayment Of Debt
-1.03
-50.22%
-0.68
-24.64%
-0.55
+3.69%
-0.57
Long Term Debt Issuance
—
—
0.00
0.00
Long Term Debt Payments
-1.03
-50.22%
-0.68
-24.64%
-0.55
+3.69%
-0.57
Net Long Term Debt Issuance
-1.03
-50.22%
-0.68
-24.64%
-0.55
+3.69%
-0.57
Short Term Debt Payments
—
—
—
0.00
Net Short Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
0.01
-94.59%
0.11
-99.75%
43.80
+4379900.00%
-0.00
Common Stock Payments
—
—
—
-0.01
Repurchase Of Capital Stock
—
—
—
-0.01
Proceeds From Stock Option Exercised
—
—
—
0.01
Net Other Financing Charges
—
-0.55
—
-0.78
Changes In Cash
-6.74
+83.39%
-40.57
-183.67%
48.49
+194.79%
-51.15
Effect Of Exchange Rate Changes
-2.74
-65.96%
-1.65
-4.56%
-1.58
-403.07%
0.52
Beginning Cash Position
36.27
-53.79%
78.49
+148.51%
31.59
-61.58%
82.22
End Cash Position
26.80
-26.13%
36.27
-53.79%
78.49
+148.51%
31.59
Free Cash Flow
-70.16
-207.50%
65.27
+206.63%
-61.21
+18.18%
-74.81
Common Stock Issuance
0.01
-94.59%
0.11
-99.75%
43.80
+625585.71%
0.01
Interest Paid CFO
-0.19
-46.51%
-0.13
+26.70%
-0.18
+63.18%
-0.48
Interest Received CFO
1.90
+21.37%
1.56
+162.69%
0.59
+762.32%
0.07
Issuance Of Capital Stock
0.01
-94.59%
0.11
-99.75%
43.80
+625585.71%
0.01
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category